Mirabegron: all 141 studies that test it

Page 1 of 2. Open to participants first (22), then studies with results posted, then the rest; newest registration first within each.

• Ancillary Nocturnal Urinary Symptoms Analyses for TRIUMPHRecruitingNCT07829029Phase 4
• Beta-3 Enhanced Autonomic Therapy for POTSNot yet recruitingNCT07585513Phase 2
• Using Mirabegron to Control Arrhythmia-1Not yet recruitingNCT07566208Phase 2
• Comparison of Mirabegron and Tamsulosin for Ureteral Stone ExpulsionRecruitingNCT07310797Phase 4
• Omegapres Versus Solifenacin and Mirabegron Combination Therapy in Treatment of Primary MNERecruitingNCT07199894Phase 3
• Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson DiseaseNot yet recruitingNCT07187466Phase 4
• The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled TrialNot yet recruitingNCT07114640Phase 3
• Study of Tamsulosin, Solifenacin and Mirabegron in Alleviating Ureteral Stent-related SymptomsRecruitingNCT06803030Phase 3
• Pegylated Liposomal Doxorubicin Plus Adebrelimab With or Without Mirabegron in Relapsed Ovarian CancerRecruitingNCT06791460Phase 2/3
• Efficacy of Solifenacin, Mirabegron and Combination Therapy in Children With Daytime Urinary Incontinence (BeDry)RecruitingNCT06551246Phase 3
• Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical StudyRecruitingNCT06534762Phase 2
• Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive BladderRecruitingNCT06479720Phase 4
• A Trial Evaluating the Clinical Efficacy and Safety of Hibero SR (Mirabegron) 50 mg and Ditropan (Oxybutynin Chloride) 10 mg in Children Between 5 and 18 Years With Overactive Bladder (OAB)Not yet recruitingNCT06181591Phase 2
• Comparisons of the Impact of Monotherapy With Mirabegron or Tolterodine Versus Combined Treatment With Mirabegron and Tolterodine on Autonomic Function and Bladder Blow Flow in Women With Overactive Bladder Syndrome: a Randomized Controlled StudyRecruitingNCT05946902Phase 4
• Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With ObesityNot yet recruitingNCT05713799Phase 2
• Mirabegron 25 mg for Treatment of Primary Nocturnal EnuresisRecruitingNCT05617664Not applicable
• Efficacy and Safety of Mirabegron in Intracerebral HemorrhageRecruitingNCT05369351Phase 2
• TReating Incontinence for Underlying Mental and Physical HealthRecruitingNCT05362292Phase 4
• Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder SyndromeRecruitingNCT05221021Phase 4
• The Effects of Mirabegron and Tadalafil on Glucose Tolerance in PrediabeticsRecruitingNCT05051436Phase 4
• Mechanisms for Activation of Beige Adipose Tissue in HumansRecruitingNCT04666636Phase 2
• Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus SolifenacinRecruitingNCT04023253Phase 3
• Using Mirabegron to Increase BP in Patients With POTSCompletedNCT06133075Phase 2Results posted
• MIrabegron and Physiological Function in Cold EnvironmentsCompletedNCT05990387Phase 1/2Results posted
• Posterior Tibial Nerve Stimulation (PTNS) Plus Mirabegron to Treat Refractory OAB Symptoms (PTNS-M Study)CompletedNCT04907032Phase 4Results posted
• Mirabegron and Physiological Function in Cold EnvironmentsCompletedNCT04766021Phase 1/2Results posted
• A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)TerminatedNCT04641975Phase 3Results posted
• A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive BladderCompletedNCT04562090Phase 4Results posted
• A Study to Investigate the Effect of Food With Mirabegron in Healthy Chinese ParticipantsCompletedNCT04501640Phase 4Results posted
• Mirabegron For Erectile DysfunctionCompletedNCT02916693Phase 1/2Results posted
• The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord InjuryCompletedNCT02893553Phase 2Results posted
• A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial CystitisTerminatedNCT02787083Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)CompletedNCT02757768Phase 4Results posted
• Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor OveractivityCompletedNCT02751931Phase 3Results posted
• Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent PainCompletedNCT02744430Phase 2Results posted
• A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)CompletedNCT02656173Phase 4Results posted
• Mirabegron in Parkinson Disease and Impaired CognitionCompletedNCT02536976Phase 4Results posted
• Mirabegron and Urinary Urgency IncontinenceCompletedNCT02495389Phase 4Results posted
• Add-on Mirabegron in Pediatric Patients With Refractory Overactive BladderCompletedNCT02476175Phase 3Results posted
• Pilot Study of Mirabegron in Pediatric Patients With Overactive BladderCompletedNCT02468830Phase 3Results posted
• Myrbetriq™ (Mirabegron) to Reduce Pain and Discomfort Following Ureteral Stent PlacementTerminatedNCT02462837Phase 2Results posted
• Treatment of Incontinence Without Memory ProblemsCompletedNCT02436889Phase 4Results posted
• Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)CompletedNCT02216214Phase 4Results posted
• A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)CompletedNCT02138747Phase 4Results posted
• A Pilot Study of Mirabegron and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Parkinson's Disease (MAESTRO)CompletedNCT02092181Phase 4Results posted
• Study of Behavioral Modification Program and Mirabegron to Improve Urinary Urgency in Multiple SclerosisCompletedNCT02086188Phase 4Results posted
• A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive BladderCompletedNCT02045862Phase 3Results posted
• Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder PatientsTerminatedNCT02044510Phase 2/3Results posted
• This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive BladderCompletedNCT01972841Phase 3Results posted
• Study of Human Non-Shivering Thermogenesis and Basal Metabolic RateCompletedNCT01950520Phase 2Results posted
• A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin)CompletedNCT01908829Phase 3Results posted
• A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder PatientsCompletedNCT01745094Phase 4Results posted
• A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.CompletedNCT01638000Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive BladderCompletedNCT01340027Phase 2Results posted
• A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00912964Phase 3Results posted
• Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00689104Phase 3Results posted
• Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00688688Phase 3Results posted
• A Study to Assess Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive BladderCompletedNCT00662909Phase 3Results posted
• A Study of Mirabegron (YM178) in Men With Lower Urinary Tract Symptoms (LUTS) and Bladder Outlet Obstruction (BOO)CompletedNCT00410514Phase 2Results posted
• Efficacy and Safety of Mirabegron Versus Oxybutynin After Posterior Urethral Valve AblationCompletedNCT07668232Not applicable
• A Pilot Study of Mirabegron and Montelukast in Cirrhotic PatientsCompletedNCT07533565Phase 4
• Double j Stent Related SymptomsCompletedNCT07447518Early Phase 1
• Efficacy of Mirabegron for Treatment of Non-monosymptomatic Nocturnal Enuresis in ChildrenActive, not recruitingNCT07398261Phase 3
• Strategy for Withdrawal of Pharmacological Treatment for Urinary Incontinence in Children (StayDry)Active, not recruitingNCT06465576Phase 4
• Management of OAB in Female Patients .CompletedNCT06184334Not applicable
• THE EFFECTS OF MIRABEGRON AND TAMSULOSIN FOR PATIENTS WITH URETERAL STENTSCompletedNCT06124066Phase 4
• Does Mirabegron Increase the Body Heat Generated by the Nervous SystemCompletedNCT06011265Early Phase 1
• Drug Interactions When DA-8010 is Co-administered With Paroxetine or Mirabegron in Healthy AdultsCompletedNCT05992428Phase 1
• Effect of Mirabegron on Promoting Brown Adipose Tissue ActivationStatus unknownNCT05779514Not applicable
• Effect of Mirabegron on Bladder ComplianceStatus unknownNCT05745584Not applicable
• ADRB3 Signaling Pathway in Human Adipose TissueActive, not recruitingNCT05634174Phase 1
• A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor OveractivityCompletedNCT05621616Phase 3
• Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical StudyStatus unknownNCT05452434Phase 4
• Sequencing and Combination of Mirabegron and TTNS in Overactive Bladder Syndrome: a Multicenter, Randomized, Open-label, Crossover TrialStatus unknownNCT05188742Phase 4
• Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive BladderStatus unknownNCT04909255Phase 4
• A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.CompletedNCT04485585Phase 1
• Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas Pharma US, Inc, Product of Japan)CompletedNCT04476966Phase 1
• Comparative Study Between Behavior Therapy and Behavior Therapy Plus Mirabegron in Sexually Active Men With OAB SymptomsCompletedNCT04420533Not applicable
• Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related SymptomsStatus unknownNCT04325880Phase 3
• Mirabegron And Ureteral Stent-related Pain (MAP) TrialStatus unknownNCT04286152Phase 3
• Beta 3 Agonist Treatment in Heart Failure-2CompletedNCT03926754Phase 2/3
• Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder SyndromeWithdrawnNCT03695822Phase 4
• Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURPStatus unknownNCT03632772Phase 2
• Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: Anticholinergic Agent vs. MirabegronCompletedNCT03612401Early Phase 1
• Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized StudyStatus unknownNCT03600766Phase 2
• Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive BladderCompletedNCT03558919Phase 4
• Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's DiseaseStatus unknownNCT03412513Phase 4
• Mirabegron in Achalasia: A Clinical and Manometric Proof of Concept Pilot StudyTerminatedNCT03411252Early Phase 1
• Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord InjuryStatus unknownNCT03187795Phase 2
• Mirabegron Treatment on Patients With Overactive Bladder Syndrome in TaiwanCompletedNCT03059134Phase 3
• The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor AgonistsCompletedNCT03049462Phase 1
• Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in TaiwanStatus unknownNCT03044912Phase 3
• Mirabegron and Brown Adipose TissueStatus unknownNCT03012113Phase 4
• Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in WomenWithdrawnNCT02981459Phase 4
• Brown Fat Activation StudyCompletedNCT02919176Early Phase 1
• Pharmacological Activation of Brown Adipose Tissue MetabolismCompletedNCT02811289Not applicable
• Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart FailureStatus unknownNCT02775539Phase 2
• Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart FailureCompletedNCT02599480Phase 2
• Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical OutcomesCompletedNCT02540707Phase 4
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)CompletedNCT02526979Phase 1

← Mirabegron overview